Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration

Retina

Volumn 27, Issue 6, 2007, Pages 713-723

  Tatar, Olcay ^a   Adam, Annemarie ^b   Shinoda, Kei ^c   Yoeruek, Efdal ^a   Szurman, Peter ^a   Bopp, Silvia ^d   Eckardt, Claus ^e   Bartz Schmidt, Karl Ulrich ^a   Grisanti, Salvatore ^a,f  

^a University Eye Hospital   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c National Hospital Organization   (Japan)

^d UNIVERSITY OF BREMEN   (Germany)

^e Augenklinik der Staedtischen Kliniken   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Age related macular degeneration; CD45; CD68; Choroidal neovascular membranes; Ki 67; Thy 1; Verteporfin photodynamic therapy

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CD34 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; CYTOKERATIN 18; ENDOGLIN; KI 67 ANTIGEN; THY 1 ANTIGEN;

ANALYTIC METHOD; CELL INFILTRATION; CELL PROLIFERATION; COMPARATIVE STUDY; INFLAMMATION; LEUKOCYTE; MACROPHAGE; PHOTODYNAMIC THERAPY; PREOPERATIVE EVALUATION; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; REVIEW; SUBRETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD34; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, THY-1; CHOROIDAL NEOVASCULARIZATION; CHOROIDITIS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KERATIN-18; LEUKOCYTES; MACROPHAGES; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES;

EID: 34447324945     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318042d3b0     Document Type: Review

References (65)

1. Hyman L. Epidemiology of eye disease in the elderly. Eye 1987;1:330-341.
2. Bressler N, Bressler S, Fine S. Age related macular degeneration. Surv Ophthalmol 1988;32:375-413.
3. Guyer D, Fine S, Maguire M, et al. Subfoveal choroidal neovascular membranes in age related macular degeneration: visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol 1986;104:702-705.
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol 1999;117:1329-1345.
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001;119:198-207.
6. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP report No. 3. Arch Ophthalmol 2002;120:1443-1454.
7. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001;131:541-560.
8. Blinder KJ, Bradley S, Bressler NM, et al. Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003;136:407-418.
9. Kaiser PK. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension TAP Report No. 8. Graefes Arch Clin Exp Ophthalmol 2006;244:1132-1142.
10. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - a value-based reappraisal with 5-year data. Am J Ophthalmol 2005;140:679-687.
11. Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 2004;111:1967-1980.
12. Park CH, Toth CA. Macular translocation surgery with 360-degree peripheral retinectomy following ocular photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 2003;136:830-835.
13. Mirshahi A, Schreyger F, Baatz H, et al. [Macular translocation after photodynamic therapy: a case report.] Klin Monatsbl Augenheilkd 2005;222:586-589.
14. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110:979-986.
15. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
16. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:632.
17. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:642.
18. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
19. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
20. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 2005;25:685-690.
21. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-645.
22. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005;123:509-516.
23. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 2002;64:162-169.
24. Yasukawa T, Kimura H, Tabata Y, et al. Active drug targeting with immunoconjugates to choroidal neovascularization. Curr Eye Res 2000;21:952-961.
25. Lee WS, Jain MK, Arkonac BM, et al. Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines. Circ Res 1998;82:845-851.
26. Karak AK, Sarkar C, Chumber S, Tandon N. MIB-1 proliferative index in parathyroid adenoma and hyperplasia. Indian J Med Res 1997;105:235-238.
27. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002;21:119-126.
28. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999;40:1891-1898.
29. Grossniklaus HE, Martinez JA, Brown VB, et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992;15:464-472.
30. Tatar O, Kaiserling E, Adam A, et al. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol 2006;124:815-823.
31. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, et al. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3586-3592.
32. Sakurai E, Anand A, Ambati BK, et al. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3578-3585.
33. Tsutsumi C, Sonoda KH, Egashira K, et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol 2003;74:25-32.
34. Nishimura T, Goodnight R, Prendergast RA, Ryan SJ. Activated macrophages in experimental subretinal neovascularization. Ophthalmologica 1990;200:39-44.
35. Tezel TH, Bora NS, Kaplan HJ. Pathogenesis of age-related macular degeneration. Trends Mol Med 2004;10:417-420.
36. Tsutsumi-Miyahara C, Sonoda KH, Egashira K, et al. The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation. Br J Ophthalmol 2004;88:1217-1222.
37. Volanti C, Gloire G, Vanderplasschen A, et al. Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy. Oncogene 2004;11:8649-8658.
38. Grant WE, Speight PM, MacRobert AJ, et al. Photodynamic therapy of normal rat arteries after photosensitisation using disulphonated aluminium phthalocyanine and 5-aminolaevulinic acid. Br J Cancer 1994;70:72-78.
39. Gollnick SO, Evans SS, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003;2:88:1772-1779.
40. Gollnick SO, Liu X, Owczarczak B, et al. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res 1997:15;3904-3909.
41. Hunt DW, Chan AH. Photodynamic therapy and immunity. Drugs 1999;2:231-236.
42. Hunt DW, Jiang H, Granville DJ, et al. Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes. Immunopharmacology 1999;41:31-44.
43. Yeh DC, Bula DV, Miller JW, et al. Expression of leukocyte adhesion molecules in human subfoveal choroidal neovascular membranes treated with and without photodynamic therapy. Invest Ophthalmol Vis Sci 2004;45:2368-2373.
44. Ghazi NG, Jabbour NM, De La Cruz ZC, Green WR. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 2001;21:478-486.
45. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195-214.
46. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120:835-844.
47. Hinton DR, He S, Lopez PF. Apoptosis in surgically excised choroidal neovascular membranes in age-related macular degeneration. Arch Ophthalmol 1998;116:203-209.
48. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855-868.
49. Lopez PF, Lambert HM, Grossniklaus HE, Sternberg P Jr. Well-defined subfoveal choroidal neovascular membranes in age-related macular degeneration. Ophthalmology 1993;100:415-422.
50. Lopez PF, Grossniklaus HE, Lambert HM, et al. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1991;15:112:647-656.
51. Grossniklaus HE, Miskala PH, Green WR, et al. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials report no. 7. Arch Ophthalmol 2005;123:914-921.
52. Seregard S, Algvere PV, Berglin L. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch Clin Exp Ophthalmol 1994;232:325-329.
53. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-422.
54. Leibovich SJ, Polverini PJ, Shepard HM, et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987;329:630-632.
55. Cousins SW, Espinosa-Heidmann DG, Csaky KG. Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization. Arch Ophthalmol 2004;122:1013-1018.
56. BenEzra D, Hemo I, Maftzir G. In vivo angiogenic activity of interleukins. Arch Ophthalmol 1990;108:573-576.
57. Jaffe GJ, Roberts WL, Wong HL, et al. Monocyte-induced cytokine expression in cultured human retinal pigment epithelial cells. Exp Eye Res 1995;60:533-543.
58. Petermeier K, Tatar O, Inhoffen W, et al. Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes. Br J Ophthalmol 2006;90:1034-1039.
59. Campochiaro PA. Ocular versus extraocular neovascularization: mirror images or vague resemblances. Invest Ophthalmol Vis Sci 2006;47:S462-474.
60. Jalili A, Makowski M, Switaj T, et al. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res 2004 1;10:4498-4508.
61. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-1545.
62. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
63. Ishibashi T, Hata Y, Yoshikawa H, et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997;235:159-167.
64. Tatar O, Shinoda K, Adam A, et al. Expression of endostatin in human choroidal neovascular membranes secondary to age-related macular degeneration. Exp Eye Res 2006;83:329-338.
65. Arras M, Ito WD, Scholz D, et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998;1:40-50.